Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 49 of 315 for:    IBRUTINIB

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02356458
Recruitment Status : Recruiting
First Posted : February 5, 2015
Last Update Posted : April 9, 2019
Sponsor:
Collaborator:
European Mantle Cell Lymphoma Network
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2022